 Examiner.com |
Monoclonal Antibody Works in Severe Asthma
MedPage Today Note that a multicenter, randomized placebo-controlled trial found that mepolizumab, a monoclonal antibody against interleukin-5, decreased asthma exacerbations, hospitalizations, and emergency department visits for patients with severe asthma and … Clinical study: New asthma drug cuts attack frequency in half GSK severe asthma drug progresses to Phase III GSK asthma drug cuts symptoms 52%; ready for PhIII |
View full post on asthma – Google News